Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Needham analyst Mike Matson upgrades TransMedics Group (NASDAQ:TMDX) from Hold to Buy and announces $148 price target.
Canaccord Genuity analyst William Plovanic maintains TransMedics Group (NASDAQ:TMDX) with a Buy and maintains $142 price tar...
Jefferies analyst Young Li initiates coverage on TransMedics Group (NASDAQ:TMDX) with a Buy rating and announces Price Targe...
Subsequently, on October 3, 2025, the Buyer acquired a fixed-wing aircraft from Teaghlach Aviation, LLC for a purchase price of...
TransMedics Group (NASDAQ: TMDX) has outperformed the market over the past 5 years by 37.76% on an annualized basis producing a...
